alendronate has been researched along with Coronary Artery Disease in 3 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The objective of this study was to determine whether the osteoporosis treatment agent alendronate accelerates the rate of CAC." | 7.71 | Progression of coronary artery calcification in patients taking alendronate for osteoporosis. ( Adams, JS; Aziz, D; Emerick, AM; Gjertson, D; Goldin, JG; Greaser, LD; Hill, JA; Khorrami, S; Yoon, HC, 2002) |
| " ISCRs for atrial fibrillation (AF), angina pectoris, arteriosclerosis coronary artery (ACA), cardiac arrhythmias, coronary artery disease (CAD), thromboembolic events (TE), ischaemic heart disease (IHD), torsade de pointes/QT prolongation (TDP) associated with alendronate, zoledronic acid and teriparatide use were extracted." | 4.31 | Cardiac adverse events in bisphosphonate and teriparatide users: An international pharmacovigilance study. ( Ebeling, PR; Nerlekar, N; Rodríguez, AJ, 2023) |
| " The objective of this study was to determine whether the osteoporosis treatment agent alendronate accelerates the rate of CAC." | 3.71 | Progression of coronary artery calcification in patients taking alendronate for osteoporosis. ( Adams, JS; Aziz, D; Emerick, AM; Gjertson, D; Goldin, JG; Greaser, LD; Hill, JA; Khorrami, S; Yoon, HC, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Généreux, P | 1 |
| Chernin, G | 1 |
| Assali, AR | 1 |
| Peruga, JZ | 1 |
| Robinson, SD | 1 |
| Schampaert, E | 1 |
| Bagur, R | 1 |
| Mansour, S | 1 |
| Rodés-Cabau, J | 1 |
| McEntegart, M | 1 |
| Gerber, R | 1 |
| L'Allier, P | 1 |
| de Silva, R | 1 |
| Daneault, B | 1 |
| Aggarwal, SK | 1 |
| Džavík, V | 1 |
| Ozan, MO | 1 |
| Ben-Yehuda, O | 1 |
| Maehara, A | 1 |
| Stone, GW | 1 |
| Jonas, M | 1 |
| Rodríguez, AJ | 1 |
| Nerlekar, N | 1 |
| Ebeling, PR | 1 |
| Hill, JA | 1 |
| Goldin, JG | 1 |
| Gjertson, D | 1 |
| Emerick, AM | 1 |
| Greaser, LD | 1 |
| Yoon, HC | 1 |
| Khorrami, S | 1 |
| Aziz, D | 1 |
| Adams, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Biorest Liposomal Alendronate Administration for Diabetic Patients Undergoing Drug-Eluting Stent Percutaneous Coronary Intervention[NCT02645799] | Phase 2 | 270 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for alendronate and Coronary Artery Disease
| Article | Year |
|---|---|
Double-blind, placebo-controlled evaluation of biorest liposomal alendronate in diabetic patients undergoing PCI: The BLADE-PCI trial.
Topics: Alendronate; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus; Drug-Eluting Stents; | 2022 |
2 other studies available for alendronate and Coronary Artery Disease
| Article | Year |
|---|---|
Cardiac adverse events in bisphosphonate and teriparatide users: An international pharmacovigilance study.
Topics: Alendronate; Bone Density Conservation Agents; Coronary Artery Disease; Diphosphonates; DNA-Binding | 2023 |
Progression of coronary artery calcification in patients taking alendronate for osteoporosis.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Bone and Bones; Calcinosis; Cal | 2002 |